Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
25 avr. 2023 15h52 HE
|
Muscular Dystrophy Association
New York, April 25, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval of Qalsody (tofersen), for the...
Muscular Dystrophy Association Announces Nearly $400K in Research Grants to Address Challenges in Duchenne Muscular Dystrophy Gene Therapy
13 mars 2023 09h00 HE
|
Muscular Dystrophy Association
New York, NY, March 13, 2023 (GLOBE NEWSWIRE) -- Today, Muscular Dystrophy Association (MDA) announced two research grants designed to address potential transgene-triggered safety concerns in...
Muscular Dystrophy Association Celebrates FDA Approval of Skyclarys, First Ever Treatment for Friedreich’s Ataxia from Reata Pharmaceuticals
28 févr. 2023 20h18 HE
|
Muscular Dystrophy Association
New York, NY, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of Omaveloxolone (Skyclarys), the first ever...
Muscular Dystrophy Association Announces Five Recipient Organizations of Advocacy Collaboration Grants
16 févr. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, NY, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the five organizations receiving $109,065 in grant funding. The grants will promote and...
Muscular Dystrophy Association and Buffalo Bills Running Back Nyheim Hines Launch Nation's Largest St. Patrick’s Day Fundraising Campaign
15 févr. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today launched the nation's largest St. Patrick's Day fundraising campaign, MDA Shamrocks. Thousands of...
Muscular Dystrophy Association’s Venture Philanthropy Program Announces Investment in Non-viral Gene Therapy
25 janv. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announces a $650,000 investment in Myosana Therapeutics via its MDA Venture Philanthropy (MVP) program....
Registration Opens for MDA Summer Camp for Children with Neuromuscular Diseases
17 janv. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, NY, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the opening of registration for its MDA Summer Camp program for children ages 8 to 17 living...
FDA’s Peter Marks, M.D., Ph.D. to deliver Keynote Address at 2023 Muscular Dystrophy Association Clinical & Scientific Conference
10 janv. 2023 06h00 HE
|
Muscular Dystrophy Association
New York, NY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Peter Marks, M.D., Ph.D. as the Keynote Speaker at the MDA 2023 Clinical & Scientific...
Muscular Dystrophy Association Elects Governor Brad Henry as Chairman and Christopher Rosa, Ph.D. as Vice Chairman of the Board of Directors
09 janv. 2023 09h20 HE
|
Muscular Dystrophy Association
New York, NY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the election of new Board of Directors leadership. Governor Brad Henry will now serve as...
Nexien BioPharma Engages Dr. Benedikt Schoser as Advisor
03 févr. 2022 09h00 HE
|
Nexien BioPharma, Inc.
DENVER, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Nexien BioPharma Inc. (OTCQB: NXEN) ("Nexien" or the "Company") today announced that it has retained Dr. Benedikt Schoser as an advisor to the Company. Dr....